20n Bio designs and screens cyclic peptides using high-throughput screening and computational methods to create peptide drugs with specific biophysical and pharmacological properties. The startup targets unmet medical needs by developing therapeutics that can effectively address various health conditions.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing peptide drugs with specific biophysical and pharmacological properties is challenging due to the vast sequence space and difficulties in optimizing stability and bioavailability. Traditional methods struggle to efficiently identify peptides with optimal binding and therapeutic characteristics for unmet medical needs.
Solution
20n Bio is a peptide discovery company that leverages high-throughput screening and chemical optimization to discover cyclic peptides for therapeutic applications. Their proprietary platform screens libraries containing trillions of peptides to identify potent candidates with desired therapeutic activity. This de novo peptide discovery approach enables the development of innovative treatments for a wide range of conditions, from metabolic disorders to complex cancers. In addition to internal pipeline development, 20n Bio partners with pharmaceutical and biotechnology companies to bring novel peptide therapeutics to market.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies seeking novel peptide therapeutics, as well as researchers and clinicians focused on developing treatments for metabolic disorders and complex cancers.
Features
- Proprietary peptide discovery platform capable of screening libraries containing trillions of peptides
- High-throughput screening efficiently navigates the peptide sequence space
- Chemical optimization refines peptides for stability and bioavailability
- Focus on de novo peptide discovery for targets lacking known natural ligands
- Versatile platform applicable to various therapeutic modalities, including oral peptides, radioligand therapy, and peptide-drug conjugates